公开(公告)号：US20080021101A1

公开(公告)日：2008-01-24

申请号：US11597459

申请日：2004-05-26

申请人： Arturo Jimenez-Bayardo ,  Jose Tornero-Montano ,  Maria Lopez-Sanchez ,  Enrique Cruz-Olmos

发明人： Arturo Jimenez-Bayardo ,  Jose Tornero-Montano ,  Maria Lopez-Sanchez ,  Enrique Cruz-Olmos

IPC分类号： A61K31/215 ,  A61P27/02

CPC分类号： A61K31/5575

摘要： A method of solubilizing an analog active agent of the prostaglandin F2α, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment.

摘要翻译： 描述了增溶前列腺素F2al的类似物活性剂如拉坦前列素的方法，以及制备用于治疗不同眼部疾病的溶解拉坦前列素的眼用溶液的方法。 本发明还涉及由上述方法得到的眼用水溶液，其特征在于其在室温下的化学稳定性，其安全性，以及对患者治疗的无害性和有效性。 新的眼用水溶液的特征在于其药物价值在易于接近的载体中被发现，其不仅允许拉坦前列素的溶解度，而且还促进其化学稳定性和对眼科应用的更大耐受性 治疗患者的疾病。